CN116083294A - Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia - Google Patents

Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia Download PDF

Info

Publication number
CN116083294A
CN116083294A CN202211469452.5A CN202211469452A CN116083294A CN 116083294 A CN116083294 A CN 116083294A CN 202211469452 A CN202211469452 A CN 202211469452A CN 116083294 A CN116083294 A CN 116083294A
Authority
CN
China
Prior art keywords
preeclampsia
strain
lactobacillus reuteri
intestinal
intestinal flora
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211469452.5A
Other languages
Chinese (zh)
Other versions
CN116083294B (en
Inventor
周宏伟
张冬鑫
李炳宇
曾山水
陈慕璇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Medical University Zhujiang Hospital
Original Assignee
Southern Medical University Zhujiang Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Medical University Zhujiang Hospital filed Critical Southern Medical University Zhujiang Hospital
Priority to CN202211469452.5A priority Critical patent/CN116083294B/en
Publication of CN116083294A publication Critical patent/CN116083294A/en
Application granted granted Critical
Publication of CN116083294B publication Critical patent/CN116083294B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The application discloses a strain, lactobacillus reuteri (Limosilactobacillus reuteri, CALM 603), with a preservation number of CGMCC No.25407. The strain has outstanding effects in regulating intestinal flora, improving vascular endothelial function, improving preeclampsia symptoms and the like, can effectively balance intestinal microecology after being planted in intestinal tracts, increases intestinal beneficial bacteria, avoids intestinal flora disorder and improves the condition of intestinal flora disorder in preeclampsia; the intervention of lactobacillus reuteri can promote the organism in preeclampsia to produce nitric oxide which is a substance for regulating vascular endothelial activity, inhibit the expression level of anti-angiogenic factors and up-regulate the expression level of pro-angiogenic factors, improve the related symptoms in preeclampsia, and has wide market application prospect.

Description

Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia
Technical Field
The application relates to the technical field of medical microorganisms, in particular to lactobacillus reuteri and application thereof in preparation of a preparation product for preventing or treating preeclampsia.
Background
Preeclampsia refers to pregnancy syndrome of pregnant women with normal pre-pregnancy blood pressure, which has clinical symptoms such as hypertension, proteinuria and the like after 20 weeks of pregnancy, is a main cause of morbidity and mortality of mothers and fetuses, seriously endangers the health of babies and infants, but clinically has no effective treatment mode except delivery, and at present, low-dose aspirin is clinically usually given for prevention or magnesium sulfate is given for alleviation when the morbidity.
A large number of researches show that normal intestinal microecology plays a vital role in maintaining human health and resisting diseases, and the intestinal microecology structure of pregnant women can be adaptively adjusted along with the occurrence and development of pregnancy, which is very important for maintaining normal pregnancy ending, and once maladaptation or dysbacteriosis occurs, pregnancy complications such as preeclampsia and the like can be caused. The research shows that the intestinal flora structure of the preeclampsia mice is abnormally changed, the bacterial abundance is obviously reduced, meanwhile, beneficial bacteria are obviously down-regulated, harmful bacteria are obviously increased, and the animal model of fecal bacteria transplantation is utilized to prove that the pregnant mice show typical clinical symptoms of preeclampsia after the preeclampsia patients are transplanted with fecal bacteria.
The probiotic products can improve intestinal microenvironment, but the conditions that the effect of improving preeclampsia by the probiotic products is not stable enough or the curative effect is not exact enough can occur, the components of the probiotic products are relatively complex, the specific beneficial components of the probiotics are not specific, the specific effects are not specific, the conditions that the effect of improving preeclampsia by different probiotic products is not stable enough or the curative effect is not exact enough can occur, and finally the real clinical effect is difficult to ensure.
Disclosure of Invention
The object of the present application is to at least partially overcome the deficiencies of the prior art and to provide a strain and the use of the strain for the preparation of a formulation product for the prevention or treatment of preeclampsia.
In order to achieve the technical purpose, the technical scheme adopted by the application is as follows:
a strain is Lactobacillus reuteri Limosilactobacillus reuteri, CALM603, and has a preservation number of CGMCC No.25407.
The use of the strain in the preparation of a formulation product for preventing or treating preeclampsia.
The preparation product is used for improving preeclampsia caused by vascular endothelial dysfunction.
The preparation product is used for regulating alpha diversity and beta diversity of intestinal flora.
The preparation product is used for improving the alpha diversity of intestinal flora. The preparation product is used for reducing colony structure difference of intestinal flora.
The preparation product is used for regulating placenta angiogenesis regulator.
The regulatory factor includes an anti-angiogenic factor, a pro-angiogenic factor, and nitric oxide.
The preparation product is used for inhibiting the expression of anti-angiogenic factors, promoting the expression of pro-angiogenic factors and promoting the synthesis of nitric oxide.
The active ingredient of the preparation product is the microbial inoculum of the strain.
The microbial inoculum comprises at least one of a strain metabolite, a culture solution, a suspension, a fermentation liquor or an extracting solution.
The product comprises at least one of medicines, microbial agents, health products, foods and food additives.
Biological preservation information:
the lactobacillus reuteri (Limosilactobacillus reuteri, CALM 603) strain is preserved in China general microbiological culture collection center (CGMCC) (address: north Chen Xi Lu No. 1, 3 of the area of Chaoyang in Beijing) for 25 days in 2022, and the preservation number is CGMCC No.25407.
Compared with the prior art, the application has the following advantages:
1) The strain can maintain intestinal microecology balance by adjusting intestinal flora structure and intestinal flora diversity, avoid preeclampsia caused by intestinal flora disorder, and relieve related symptoms by intervention of the strain after preeclampsia occurs.
2) The strain can promote the organism to produce and regulate vascular endothelial active substances and promote the expression of the angiogenesis factors by regulating the angiogenesis regulatory factors, inhibit the expression of the anti-angiogenesis factors, further improve the vascular endothelial cell function and realize the aim of improving preeclampsia.
3) The strain can be applied to medicines, health products, foods and food additives for industrialized application, and has wide market prospect.
Drawings
FIG. 1 is a colony growth morphology of the strain of the present application cultured on MRS plates;
FIG. 2 shows the mass spectrum identification results of the strain of the present application;
FIG. 3 is a graph showing the results of intestinal colonization of a preeclampsia mouse model by the strain of the present application;
FIG. 4 is a graph showing the effect of the strain of the present application on the modulation of intestinal flora α diversity in a preeclampsia mouse model;
FIG. 5 is a graph showing the effect of the strain of the present application on the regulation of β -diversity in intestinal flora in a preeclampsia mouse model;
FIG. 6 is a graph showing the effect of the applied strain on the regulation of intestinal flora structure in a preeclampsia mouse model;
FIG. 7 is a graph showing the effect of the strains of the present application on the intervention of a preeclampsia mouse model;
FIG. 8 is a graph showing the effect of the strain of the present application on placental angiogenesis in a pre-eclamptic mouse model;
FIG. 9 is a graph showing the effect of the strain of the present application on placental angiogenesis modulators in a pre-eclamptic mouse model;
FIG. 10 is a graph showing the regulation of nitric oxide synthesis by the strains of the present application in a pre-eclamptic mouse model.
Detailed Description
The present application is described in further detail below with reference to the drawings and detailed description.
Culture and identification of CALM603
Lactobacillus reuteri (Limosilactobacillus reuteri, CALM 603) of the present application was obtained by laboratory autonomous isolation screening, and identified by 16S rDNA sequencing and mass spectrometry.
Lactobacillus reuteri obtained by laboratory screening was inoculated directly on MRS medium, and the medium was subjected to anaerobic culture at 37 ℃ for 28 hours to obtain growing colonies, as shown in fig. 1.
And respectively extracting a plurality of single colony DNAs, amplifying and measuring the 16S rDNA sequences of the single colonies, comparing the sequences, simultaneously carrying out mass spectrum identification on the strain, and screening through a series of functional experiments to obtain the strain, wherein the strain is lactobacillus reuteri (Limosilactobacillus reuteri, CALM 603) capable of improving preeclampsia and vascular endothelial functions, the sequence of the 16S rDNA is shown as SEQ ID N0.1, and the mass spectrum identification result is shown as figure 2.
CALM603 applied to animal model experiments
ABX gastric lavage treatment is performed on mice to kill intestinal microorganisms in the mice, resulting in relatively sterile mice. ABX gastric lavage treatment refers to the use of antibiotics, typically tetranectins, including vancomycin (vancomycin), penicillin (ampicillin), metronidazole (metronidazole), and neomycin (neomycin sulfate).
(1) 18 female C57BL/6j mice of 8 weeks of age were randomly assigned to control group (CTRL), preeclampsia model group (L-NAME), lactobacillus reuteri intervention group
(L-NAME+ L.r), 6 mice per group.
(2) Mice were placed in animal centers for 5 days of acclimatization. After 5 days, based on
There were mice treated with ABX lavage for 5 consecutive days, the concentration of the tetrad antibiotic was as follows:
vancomycin,100mg/kg; neomycin sulfate, metaronidazole and
ampicillin,200mg/kg。
(3) The mice are pregnant in a closed cage, and during the period of 9.5 to 17.5 days of gestation, the mice are used for treating epilepsy
Pre-modeling module and lactobacillus reuteri intervention group were performed subcutaneously on the back of the neck for 9 consecutive days
L-NAME (40 mg/kg/day) was injected, while the control group was injected with PBS simultaneously. And (3) with
At the same time, the Lactobacillus reuteri intervention group continuously performs the gastric lavage intervention of the Lactobacillus reuteri in 0.5 to 17.5 days of gestation (1×10) 9 CFU/mL,200 ul/day). Mouse faeces were collected on day 17.5 of gestation.
(4) Fecal DNA was extracted using a QIAamp PowerFecal DNA Kit (Qiagen) kit, where the abundance of colonization of the gut by lactobacillus reuteri was detected by qPCR, and the results of the flora were amplified and library constructed based on the V4 segment of the 16S rRNA gene, high throughput sequencing was performed by Illumina MiSeq platform, and finally bioinformatic analysis was performed on the sequencing result data.
As shown in fig. 3 (l. Reuteri and L.r represent lactobacillus reuteri shorthand in all figures), the abundance of lactobacillus reuteri in the preeclampsia modeling group was significantly lower than that in the control group, while the abundance of lactobacillus reuteri was multiplied in the lactobacillus reuteri intervention group. Therefore, the lactobacillus reuteri has strong in vivo colonization capability, the abundance of the lactobacillus reuteri in the intestinal tract can be effectively changed through the intervention of the lactobacillus reuteri, the content of the lactobacillus reuteri in the intestinal tract is improved, and the microecology of intestinal flora is improved, so that the aim of improving the preeclampsia symptoms is fulfilled.
Alpha diversity refers to diversity within a particular area or ecosystem, and is a comprehensive indicator reflecting richness and uniformity. Alpha diversity is primarily related to two factors: first is the number of individual species, i.e., richness; and secondly, diversity of species, and uniformity in the number of species in a community.
The index of the community richness mainly comprises a Chao1 index, and the larger the Chao1 index is, the higher the richness of the community is; the sampled OUTs represent species type information; PD whole tree is a diversity index calculated based on phylogenetic tree, it constructs the distance of phylogenetic tree with the representative sequence of OTUs in each sample, add the branch length of all representative sequences in a certain sample, thus the value obtained, the larger the value, the higher the community diversity; shannon index comprehensively considers the richness and uniformity of communities, and the higher Shannon index value is, the higher the diversity of communities is indicated.
As shown in fig. 4, the indexes of the pre-eclampsia module were significantly lower than those of the control group and the lactobacillus reuteri intervention group, so that the intestinal flora enrichment and diversity of the module were the lowest; the indexes of the interference group of the lactobacillus reuteri are close to those of the control group, so that the method can be used for effectively improving the richness and diversity of intestinal flora of a preeclampsia mouse through the interference of the lactobacillus reuteri, enabling the intestinal flora to be close to the intestinal environment of a normal organism, maintaining intestinal microecological balance, avoiding intestinal flora disorder and further avoiding pregnancy complications such as preeclampsia.
Beta diversity is often used to compare differences between different ecosystems, reflecting heterogeneity of biological species due to the environment, and in general terms, different treatments (environmental, health, etc.) can lead to changes in the community structure.
As shown in fig. 5, the intestinal flora distribution (beta diversity) of the preeclampsia modeling group is significantly deviated from that of the control group and the intervention group, so that the intestinal flora of the modeling group is significantly different, and the intestinal flora is disordered; the intestinal flora distribution of the lactobacillus reuteri intervention group is obviously regressed compared with that of the control group. Therefore, the interference of lactobacillus reuteri can effectively adjust the difference between intestinal flora, promote the intestinal flora to maintain a stable environment, and avoid the phenomenon of flora disturbance.
As shown in FIG. 6, compared with the control group, the flora structure of the preeclampsia modeling group has obviously reduced intestinal firmicutes and Proteus and increased bacteroides, so that the preeclampsia can influence the intestinal flora structure and deviate the intestinal flora structure; the intestinal flora structure distribution of the Lactobacillus reuteri intervention group is close to that of the control group, the intestinal thick-wall fungus of the mice is increased by the intervention of the Lactobacillus reuteri, and the bacteroides is reduced to be close to that of the control group.
Intervention effect of CALM603 on preeclampsia mouse model
The clinical manifestations of preeclampsia are mainly: hypertension, proteinuria, fetal growth limitation, and pathological lesions of the placenta and kidneys. Therefore, the experiment can evaluate the intervention effect of the lactobacillus reuteri on the preeclampsia according to the clinical manifestation.
As shown in fig. 7, graph a shows that the blood pressure of the preeclampsia modeling group was continuously increased, significantly higher than that of the intervention group and the control group, while the blood pressure of the lactobacillus reuteri intervention group was always leveled with that of the control group, and the blood pressure was not significantly different. Therefore, the condition of hypertension of a preeclampsia mouse can be effectively improved through the intervention of lactobacillus reuteri; the diagram B shows proteinuria, and the diagram shows that the proteinuria of the preeclampsia modeling group is worse than that of the control group and the intervention group, and the proteinuria of a preeclampsia mouse can be effectively improved through the intervention of lactobacillus reuteri, so that the intervention group and the control group tend to be close; the graph C shows the sizes of the placenta and the fetus of the mice, and the placenta and the fetus of the preeclampsia modeling group can be observed to be obviously smaller than those of a control group and an intervention group through naked eyes, and the problems of the sizes of the placenta and the fetus of the preeclampsia mice can be effectively improved through the intervention of lactobacillus reuteri; the graph D shows the weight of the fetus and placenta from left to right, and shows the weight of the fetus and the weight of the placenta, and the graph shows that the interference group and the control group of the lactobacillus reuteri are higher than the preeclampsia modeling group, the data of the interference group are close to the control group, and the weight of the fetus of the preeclampsia mouse can be effectively improved through the interference of the lactobacillus reuteri, so that the normal development of the fetus is facilitated; as shown in a diagram E, the diagram shows the injury condition of the glomerulus of the mice, compared with a control group, the preeclampsia modeling group can obviously observe the abnormal glomerulus structure and endothelial hyperplasia, and the injury condition of the glomerulus of the preeclampsia mice can be effectively improved through the intervention of lactobacillus reuteri; as shown in the diagram F, the diagram shows the damage condition of the placenta of the mice, and the ratio of the placenta labyrinth area of the preeclampsia modeling module to the connecting area is increased, the vascular endothelial hyperplasia of the labyrinth area is observed, and the damage condition of the placenta of the preeclampsia mice can be effectively improved through the intervention of lactobacillus reuteri.
The above results indicate that L-NAME-induced development of preeclampsia symptoms was somewhat alleviated by the intervention of Lactobacillus reuteri, and that each indicator tended to be in normal mice.
Regulating effect of CALM603 on placenta vascular endothelial function of preeclampsia mouse model
As shown in fig. 8, placental vascular endothelial cells were labeled with CD31 (green fluorescence). The graph shows that the interference of the lactobacillus reuteri can effectively improve the generation condition of the placental vascular endothelial cells in preeclampsia, and the lactobacillus reuteri has obvious promotion effect on the placental angiogenesis of the preeclampsia mice.
As shown in FIG. 9, the preeclampsia modeling group has a remarkable promotion effect on the expression of the anti-angiogenic factor sFlt-1 and has an inhibition effect on the expression of the pro-angiogenic factor PlGF; the Lactobacillus reuteri intervention group has an inhibitory effect on the expression of the anti-angiogenic factor sFlt-1, while having an accelerating effect on the expression of the pro-angiogenic factor PlGF. Therefore, the expression of the placenta vascular endothelial function related regulator can be effectively regulated through the intervention of lactobacillus reuteri, the angiogenesis is promoted, the development of the placenta is ensured, and the preeclampsia related symptoms are avoided.
As shown in fig. 10, lactobacillus reuteri has a promoting effect on nitric oxide synthesis in preeclampsia mice. The nitrogen monoxide level in the serum of a preeclampsia mouse can be effectively increased through the intervention of lactobacillus reuteri; lactobacillus reuteri promotes up-regulation of phosphorylation levels of pre-eclamptic mouse placental nitric oxide synthase eNOS (endothelial nitric oxide synthase), where p-eNOS represents phosphorylated eNOS and β -actin represents β actin.
Application of CALM603
The strain can be prepared into a microbial inoculum and applied to oral products such as medicines, foods, food additives, health products and the like, or can be used for intervening preeclampsia and vascular endothelial dysfunction by means of intravenous transfusion or intramuscular injection and the like.
The oral product takes the microbial inoculum of the strain as an active component, and plays the role of improving or treating preeclampsia and vascular endothelial dysfunction after entering a human body through an oral mode. The oral products include, but are not limited to, liquid beverages, extracts, powders, pills, granules/powders, capsules, tablets, pills, and the like, by dosage form classification. In order to realize the formulation, auxiliary materials which can be used in food and pharmaceutical preparations are added in the preparation process: such as fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, and the like. The filler comprises: starch, lactose, mannitol, microcrystalline cellulose, sucrose, xylitol, and the like; the disintegrating agent comprises: starch, microcrystalline cellulose, sodium carboxymethyl starch, low-substituted sodium hydroxypropyl cellulose, and the like; the lubricant comprises: talc, silica, sodium lauryl sulfate, magnesium stearate, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, agar, hydroxymethyl cellulose, and the like; the adhesive comprises: starch slurry, polyvinylpyrrolidone, hydroxymethyl cellulose, and the like; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, etc.; the flavoring agent comprises: sweetener and various flavors; the preservative comprises: nipagin, benzoic acid, sodium benzoate, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil, sorbic acid and salts thereof, etc. The auxiliary materials are not only used for shaping various dosage forms, but also used for protecting active components of oral products and avoiding inactivation caused by the influence of external environment.
The injection intervention takes the bacterial agent of the strain as an active component, and uses sterile water or physiological saline to re-dissolve the bacterial agent or the preparation containing the strain to obtain injection, injection liquid, and the effect of improving or treating preeclampsia and vascular endothelial dysfunction is exerted after the injection enters a human body in an injection or infusion mode.
In summary, the strain of the application is lactobacillus reuteri (Limosilactobacillus reuteri, CALM 603), the preservation number of the strain is CGMCC No.25407, and the strain of the application is utilized to regulate intestinal microecology so as to achieve the purpose of treating preeclampsia, and has the advantages of low cost, small risk, almost no side effect, easy clinical transformation and the like. After lactobacillus reuteri is planted in the intestinal tract, intestinal microecology can be effectively balanced, beneficial intestinal bacteria are increased, intestinal flora disturbance is avoided, and the situation of intestinal flora disturbance in preeclampsia is improved; the intervention of lactobacillus reuteri can promote the organism in preeclampsia to produce nitric oxide which is a substance for regulating vascular endothelial activity, up-regulate the expression level of the angiogenesis promoting factors, improve the related symptoms in preeclampsia and have wide market application prospect.
The above embodiments are preferred embodiments of the present application, but are not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principles of the present application should be made by the equivalent substitution methods, and are included in the protection scope of the present application.

Claims (11)

1. A strain, which is lactobacillus reuteri Limosilactobacillus reuteri,
CALM603, the preservation number of the strain is CGMCC No.25407.
2. Use of a strain according to claim 1 for the preparation of a formulation product for the prevention or treatment of preeclampsia.
3. The use according to claim 2, wherein the formulation product is for ameliorating preeclampsia caused by vascular endothelial dysfunction.
4. The use according to claim 2, wherein the formulation product is for modulating intestinal flora alpha-diversity and beta-diversity.
5. The use according to claim 4, wherein the formulation product is for increasing intestinal flora alpha diversity; the preparation product is used for reducing colony structure difference of intestinal flora.
6. The use of claim 2, wherein said formulation product is for modulating a placental angiogenesis regulator.
7. The use according to claim 6, wherein the regulatory factor comprises an anti-angiogenic factor, a pro-angiogenic factor and nitric oxide 。
8. The use according to claim 7, wherein the formulation product is for inhibiting the expression of an anti-angiogenic factor, promoting the expression of a pro-angiogenic factor and promoting nitric oxide synthesis.
9. The use according to claim 2, wherein the active ingredient of the formulated product is a microbial inoculum of the strain.
10. The microbial agent of claim 9, wherein the microbial agent comprises at least one of a metabolite, a culture solution, a suspension, a fermentation solution, or an extract of a strain.
11. The use of claim 2, wherein the formulation product comprises at least one of a pharmaceutical, a nutraceutical, a food, and a food additive.
CN202211469452.5A 2022-11-22 2022-11-22 Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia Active CN116083294B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211469452.5A CN116083294B (en) 2022-11-22 2022-11-22 Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211469452.5A CN116083294B (en) 2022-11-22 2022-11-22 Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia

Publications (2)

Publication Number Publication Date
CN116083294A true CN116083294A (en) 2023-05-09
CN116083294B CN116083294B (en) 2023-10-13

Family

ID=86198166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211469452.5A Active CN116083294B (en) 2022-11-22 2022-11-22 Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia

Country Status (1)

Country Link
CN (1) CN116083294B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170020930A1 (en) * 2015-07-21 2017-01-26 Therapeutic Solutions International, Inc. Prevention of pregnancy complications by probiotic administration
CN111265553A (en) * 2020-01-23 2020-06-12 湖南菲勒生物技术有限公司 Application of lactobacillus reuteri from breast milk to adjustment of maternal and infant immune functions
CN114410533A (en) * 2022-01-27 2022-04-29 江南大学 Application of lactobacillus reuteri CCFM1040 in relieving and preventing atherosclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170020930A1 (en) * 2015-07-21 2017-01-26 Therapeutic Solutions International, Inc. Prevention of pregnancy complications by probiotic administration
CN111265553A (en) * 2020-01-23 2020-06-12 湖南菲勒生物技术有限公司 Application of lactobacillus reuteri from breast milk to adjustment of maternal and infant immune functions
CN114410533A (en) * 2022-01-27 2022-04-29 江南大学 Application of lactobacillus reuteri CCFM1040 in relieving and preventing atherosclerosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BINGYU LI ET AL.: "Limosilactobacillus reuteri ameliorates preeclampsia in mice via improving gut dysbiosis and endothelial dysfunction", BIOMEDICINE &PHARMACOTHERAPY, vol. 161, pages 1 - 10 *
KLAVDIJA Cˇ UCˇEK TRIFKOVIC ET AL.: "Efficacy of Direct or Indirect Use of Probiotics for the Improvement of Maternal Depression during Pregnancy and in the Postnatal Period: A Systematic Review and Meta-Analysis", HEALTHCARE, vol. 10, no. 970, pages 1 - 16 *
庞洁等: "罗伊氏乳杆菌的益生功能", 中国生物工程杂志, vol. 31, no. 5, pages 131 - 137 *

Also Published As

Publication number Publication date
CN116083294B (en) 2023-10-13

Similar Documents

Publication Publication Date Title
CN110101722B (en) Application of composite probiotic preparation in preparation of product for treating ulcerative colitis
Eykyn et al. Metronidazole and anaerobic sepsis.
JP2015512936A (en) Prebiotic composition and method of use thereof
US20180117100A1 (en) Lactobacillus sp. strain having ability to inhibit proliferation of virginal pathogenic microorganisms
MacFarlane et al. Bacteraemia in diabetics
EP2415475B1 (en) Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum
CN109402002B (en) Lactobacillus gasseri and application thereof in preparation of premature delivery prevention medicine
CN113122466B (en) Enterococcus faecalis and application thereof
CN115109734B (en) Lactobacillus agilis B13T4 with function of relieving hyperuricemia and application thereof
CN116083325B (en) Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof
CN115287240A (en) Lactobacillus plantarum with hyperuricemia and gout prevention and treatment effects and application thereof
CN113913346A (en) Lactobacillus paracasei JN-1 and application thereof
CN113717883B (en) Lactobacillus plantarum FLPL05 for promoting body health and longevity and application thereof
CN117143783B (en) Saliva combined lactobacillus VB330 and application thereof
CN116083294B (en) Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia
US20210069266A1 (en) Methods for the isolation of microbes with enhanced persistance and compositions with such microbes
CN112322553A (en) Clostridium difficile resistant lactococcus lactis and application thereof
CN115466699A (en) Panda-derived lactobacillus salivarius and application thereof in treating or preventing inflammatory bowel disease
CN114672436A (en) Lactobacillus acidophilus and application thereof
CN114836349A (en) Lactobacillus acidophilus LA16 for antagonizing helicobacter pylori and application thereof
CN109954004B (en) Application of bacteroides fragilis extract in preparation of composition for preventing and treating psoriasis
CN111296842A (en) Probiotic composition with anti-allergy effect
CN116376770B (en) Application of lactobacillus rhamnosus RH0121 in preparation of hypoglycemic products
CN117106622B (en) Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids
CN117946949B (en) Acremonium muciniphilum and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant